Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
Myuran Thana(Queen Elizabeth II Health Sciences Centre), Lori Wood(Dalhousie University), M. Neil Reaume(The University of Melbourne), Aaron R. Hansen(Princess Margaret Cancer Centre), Naveen S. Basappa, Rodney H. Breau(University of Ottawa), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Frédéric Pouliot(Université Laval), Georg A. Bjarnason(Sunnybrook Health Science Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Vincent Castonguay(Centre hospitalier universitaire de Québec), Christian Kollmannsberger(BC Cancer Agency), Jeffrey Graham(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
|The Journal of Urology|2019|482
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322